Anders Fink-Jensen, MD, DMSci
11
2
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
9.1%
1 terminated/withdrawn out of 11 trials
80.0%
-6.5% vs industry average
27%
3 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
Role: lead
Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder
Role: lead
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Role: lead
Involvement of the Septal Nuclei of the Human Brain in Alcohol Use Disorder
Role: lead
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
Role: lead
Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study
Role: lead
Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?
Role: lead
COVID-19 Serological Testing of Patients With a Mental Disorder From the Catchment Area of the Capital Region of Denmark
Role: lead
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
Role: lead
Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans?
Role: lead
The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring.
Role: lead
All 11 trials loaded